摘要
目的ｐ１６／ＣＤＫＮ２基因是新近发现的肿瘤抑制基因，已有研究表明该基因在许多肿瘤出现缺失、突变或重排．胃癌细胞系中有高频率纯合子缺失，应用Ｓｏｕｔｈｅｒｎｂｌｏｔ和ＳＳＣＰ技术在胃癌手术标本中未发现有该基因的缺失．本文首次研究胃癌中ｐ１６／ＣＤＫＮ２基因在蛋白水平的表达．方法应用蛋白Ａ金探针免疫组化技术对３０例胃癌和２０例正常胃粘膜标本的ｐ１６进行分析．结果所有正常对照组均有ｐ１６表达，其阳性细胞百分率为７２５５％±１７２２％；而胃癌中的阳性细胞百分率为５４９０％±２８９０％，明显低于正常对照（Ｐ＜００５）．在肿瘤病例中有２３３３％（７／３０）ｐ１６表达减低，１０％（３／３０）未表达ｐ１６．此外有１例呈过度表达．结论胃癌中有ｐ１６的异常表达，免疫组化技术可能较准确地反映ｐ１６的表达，更适合于临床研究．
AIM To investigate for the first time p16/CDKN2 gene expression at protein level in human gastric cancer. p16/CDKN2 gene is a newly identified tumor suppresser gene and has been shown to be deleted, mutated, or rearranged in numerous human tumors. Recently, homozygous deletion of the p16/CDKN2 gene has been reported in gastric cancer cell lines with high frequency,but none in surgical specimens of gastric adenocarcinomas by Southern blot and SSCP analysis.
